SCHEMBL102893

SCHEMBL102893

Cn1c(C=O)nc2ccccc21

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 12/20 0.64
ALDH1A1 P00352 9/20 0.62
MAPT P10636 8/20 0.62
RAB9A P51151 6/20 0.62
NPC1 O15118 5/20 0.62
KMT2A Q03164 4/20 0.62
PKM P14618 2/20 0.62
L3MBTL1 Q9Y468 1/20 0.62
HPGD P15428 6/20 0.57
HSD17B10 Q99714 1/20 0.57
SMN1; SMN2 Q16637 5/20 0.55
POLB P06746 3/20 0.54
GAA P10253 3/20 0.54
LMNA P02545 2/20 0.53
CDK5 Q00535 1/20 0.53
PAX8 Q06710 1/20 0.53
CDK5R1 Q15078 1/20 0.53
RCE1 Q9Y256 1/20 0.53
HTT P42858 3/20 0.52
TDP1 Q9NUW8 2/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6854119 0.82 KDM4E (0.64) KDM4EALDH1A1MAPTRAB9ANPC1
SCHEMBL6854120 0.82 KDM4E (0.64) KDM4EALDH1A1MAPTRAB9ANPC1
SCHEMBL7408413 0.82 KDM4E (0.46) KDM4EALDH1A1MAPTRAB9ANPC1
Amantadine SCHEMBL15013442 0.82 KDM4E (0.48) KDM4EALDH1A1MAPTRAB9ANPC1
SCHEMBL11699121 0.81 KDM4E (0.64) KDM4EALDH1A1MAPTRAB9ANPC1
SCHEMBL10641389 0.80 KDM4E (0.59) KDM4EALDH1A1MAPTRAB9ANPC1
SCHEMBL7191387 0.80 VDR (0.50) KDM4EALDH1A1MAPTRAB9ANPC1
SCHEMBL17254599 0.79 KDM4E (0.70) KDM4EALDH1A1MAPTRAB9ANPC1
SCHEMBL12460834 0.79 KDM4E (0.72) KDM4EALDH1A1MAPTRAB9ANPC1
SCHEMBL9335463 0.78 KDM4E (0.71) KDM4EALDH1A1MAPTRAB9ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 396 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-110627819-B Dysprosium complex constructed by benzimidazole derivative and 1, 2-cyclohexanediamine as well as preparation method and application thereof 广西师范大学 2021-04-06 CN claimed
CN-110698502-B Rare earth complex constructed by benzimidazole derivative and 1, 2-cyclohexanediamine and preparation method and application thereof 广西师范大学 2021-04-06 CN claimed
CN-108164566-B Complex capable of activating and regulating immune system and preparation method and application thereof 广西师范大学 2020-10-16 CN claimed
CN-110698502-A Rare earth complex constructed by benzimidazole derivative and 1, 2-cyclohexanediamine and preparation method and application thereof 广西师范大学 2020-01-17 CN claimed
CN-110627819-A Dysprosium complex constructed by benzimidazole derivative and 1, 2-cyclohexanediamine as well as preparation method and application thereof 广西师范大学 2019-12-31 CN claimed
EP-2245132-B1 ENCAPSULATED BENEFIT AGENT UNILEVER PLC NO 41424 (GB) 2017-10-18 EP claimed
US-20040132807-A1 Aurones as telomerase inhibitors PHARMACIA ITALIA SPA (IT) 2004-07-08 US claimed
EP-1381359-A1 AURONES AS TELOMERASE INHIBITORS Pharmacia Italia S.p.A. (IT) 2004-01-21 EP claimed
WO-2002083123-A1 AURONES AS TELOMERASE INHIBITORS PHARMACIA ITALIA SPA (IT) 2002-10-24 WO claimed
US-12570626-B2 Degraders and degrons for targeted protein degradation C4 THERAPEUTICS, INC. (US) 2026-03-10 US disclosed
CN-121574128-A Pyrimidine-hydroxamic acid compounds and uses thereof 华东理工大学 2026-02-27 CN disclosed
US-20260022114-A1 N-(5-SUBSTITUTED-[(1,3,4-THIADIAZOLYL) OR (1,3-THIAZOLYL)](SUBSTITUTED)CARBOXAMIDE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF PREPARING THE AMIDE COMPOUNDS AND OF THEIR USE GILEAD SCIENCES, INC. 2026-01-22 US disclosed
EP-4594316-A1 N-(5-SUBSTITUTED-[(1,3,4-THIADIAZOLYL) OR (1,3-THIAZOLYL)](SUBSTITUTED)CARBOXAMIDE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF PREPARING THE AMIDE COMPOUNDS AND OF THEIR USE Repare Therapeutics Inc. (CA) 2025-08-06 EP disclosed
US-20250026748-A1 N-(5-SUBSTITUTED-[(1,3,4-THIADIAZOLYL) OR (THIAZOLYL)])(SUBSTITUTED)CARBOXAMIDE COMPOUNDS AND USE THEREOF FOR INHIBITING HUMAN POLYMERASE THETA REPARE THERAPEUTICS INC. (CA) 2025-01-23 US disclosed
EP-0276942-A1 6-Beta(substituted)-(S)-hydroxymethylpenicillanic acids and derivatives thereof PFIZER INC. (US) 1988-08-03 EP disclosed
US-4390693-A BACTERICIDE MERCK & CO., INC. (US) 1983-06-28 US disclosed
US-4371607-A 4-Halogeno-5-(halogenomethyl-phenyl)-oxazole derivatives, a process for the preparation thereof, and radiation-sensitive compositions containing these derivatives HOECHST AKTIENGESELLSCHAFT (DE) 1983-02-01 US disclosed
EP-0041675-A2 4-Halogen-5-(trichloromethyl-phenyl)-oxazole derivatives, process for preparing them and radiation-sensitive compositions containing them HOECHST AKTIENGESELLSCHAFT (DE) 1981-12-16 EP disclosed
US-4255423-A BACTERICIDES MERCK & CO., INC. (US) 1981-03-10 US disclosed
US-4017313-A Photosensitive composition containing a leuco dye, a photosensitizer, an aromatic aldehyde and a secondary or tertiary amine and the use thereof in a direct-print process E. I. DU PONT DE NEMOURS AND COMPANY (US) 1977-04-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260022114-A1 N-(5-SUBSTITUTED-[(1,3,4-THIADIAZOLYL) OR (1,3-THIAZOLYL)](SUBSTITUTED)CARBOXAMIDE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF PREPARING THE AMIDE COMPOUNDS AND OF THEIR USE POLK, POLQ, POLB KDM4E 1824/4885ALDH1A1 3422/4885MAPT 1741/4885
US-20250026748-A1 N-(5-SUBSTITUTED-[(1,3,4-THIADIAZOLYL) OR (THIAZOLYL)])(SUBSTITUTED)CARBOXAMIDE COMPOUNDS AND USE THEREOF FOR INHIBITING HUMAN POLYMERASE THETA POLA1, POLL, POLD1 KDM4E 2958/4885ALDH1A1 789/4885MAPT 4688/4885
US-12570626-B2 Degraders and degrons for targeted protein degradation ADRM1, UCHL3, USP30 KDM4E 2163/4885ALDH1A1 3506/4885MAPT 3677/4885
US-20040132807-A1 Aurones as telomerase inhibitors TERT, TERF2, TERF2IP KDM4E 818/4885ALDH1A1 1344/4885MAPT 1433/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.